The combination of belzutifan (Welireg) and lenvatinib (Lenvima) led to superior outcomes, compared with cabozantinib (Cabometyx), in a phase 3 trial of patients with advanced clear cell renal cell ...
Differences in the clinical course and treatment responses in individual patients with advanced renal cell carcinoma (RCC) can largely be explained by the different genomics of this disease. To ...
Allogene Therapeutics (ALLO) will concurrently present new data from the Phase 1 TRAVERSE trial in an oral presentation at the 2024 International Kidney Cancer Symposium and a poster session at The ...
Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy ...
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...
Diagnosed With Advanced Renal Cell Carcinoma: Why You May Want a Second Opinion, and How to Find One
Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...
Credit: Getty Images. Belzutifan is a hypoxia-inducible factor inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental News Drug Application (sNDA) for ...
Tumor growth, metastasis and therapeutic response are believed to be regulated by the tumor and its microenvironment (TME) in advanced renal cell carcinoma (RCC). However, the mechanisms underlying ...
Female pharmacist giving a tablet bottle to patient A 120 mg daily dose of belzutifan is appropriate for previously treated, advanced clear cell RCC, results from the LITESPARK-013 trial suggest. A ...
MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older ...
Interim analysis showed pembrolizumab/lenvatinib plus belzutifan failed to improve OS or reduce progression/death risk versus pembrolizumab/lenvatinib in first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results